Department / Division
Medicine / Medicine - Hematological Malignancies
Durham, NC 27710
Treatment of hematologic malignancies, clinical trials in lymphoma
My particular area of research interest is clinical trails for patients with lymphoma.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
Beaven, AW; Shea, TC; Moore, DT; Feldman, T; Ivanova, A; Ferraro, M; Ford, P; Smith, J; Goy, A. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma. 2012;53:254-258. (2012) Abstract
Beaven, AW; Moore, DT; Sharf, A; Serody, JS; Shea, TC; Gabriel, DA. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Investigation. 2011;29:214-219. (2011) Abstract
Dorth, JA; Chino, JP; Prosnitz, LR; Diehl, LF; Beaven, AW; Coleman, RE; Kelsey, CR. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Annals of Oncology. 2011;22:405-410. (2011) Abstract
Kelsey, CR; Beaven, AW; Diehl, LF; Prosnitz, LR. Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?. Oncology. 2010;24:1204-1212. (2010) Abstract
Shea, TC; Beaven, AW; Moore, DT; Serody, JS; Gabriel, DA; Chao, N; Gockerman, JP; Garcia, RA; Rizzieri, DA. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia and Lymphoma. 2009;50:741-748. (2009) Abstract